Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04970056

Pancreatic Cancer Early Detection Consortium

Status
Recruiting
Phase
Study type
Observational
Enrollment
20,000 (estimated)
Sponsor
Arbor Research Collaborative for Health · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Accepted

Summary

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

Detailed description

The main objective of the PRECEDE Consortium is to build a shared resource to drive research in critical areas necessary for early detection and prevention of PDAC. The PRECEDE Consortium is an observational prospective cohort study, with single or serial biosample collection (every 6-12 months) in defined high-risk groups. A standardized procedure for collection and processing of human blood for the PRECEDE Consortium will be applied to all blood samples collected as part of the study. Barcoded samples will be stored at the clinical centers, using the specific labels for the PRECEDE study and corresponding data will be entered into the study database. Clinical data and outcomes will be obtained from institutional databases or clinical records to correlate patient information with laboratory results from biospecimens obtained for research. Patients will be followed by their attending physician and receive the standard follow-up care after the procedure in which biospecimen was obtained. It is the intent that biospecimens will be made available to all consortium investigators.

Conditions

Timeline

Start date
2020-09-18
Primary completion
2030-12-31
Completion
2030-12-31
First posted
2021-07-21
Last updated
2026-01-28

Locations

60 sites across 11 countries: United States, Australia, Canada, Hungary, Iceland, Israel, Italy, Singapore, Spain, Taiwan, United Kingdom

Source: ClinicalTrials.gov record NCT04970056. Inclusion in this directory is not an endorsement.